Store
Cell and Gene Therapy Deals, 2022
Publication Date: February 17, 2022
Tags: CAR-T Cell Therapy, Cell and Gene Therapy, Funding and Investments, Life Science, Mergers and Acquisitions (M&A), Oncology and Cancer
Pages: 155
SKU: 22-054
The cell and gene therapy (CGT) sector has experienced remarkable growth, with funding reaching $70 billion in 2021. As barriers to entry lower and the number of approved therapies with proven track records increases, over a thousand companies have entered or expanded within this dynamic field. Keeping up with this rapidly evolving industry is essential, and Kalorama Information’s latest report, Cell and Gene Therapy Deals: Financings, Partnering, M&A, Technology Transfers, IPOs, and Other Developments, 2022, provides comprehensive insights into the myriad deals shaping the CGT landscape.
Key Highlights:
- Funding and Investments: Detailed analysis of the financial influx into CGT-related companies, including IPOs, SPACs, venture capital, and private funding.
- Strategic Deals: Insight into mergers & acquisitions, strategic investments, technology and research collaborations, and licensing agreements.
- Operational Transactions: Examination of manufacturing and supply chain deals, public outreach efforts, consumer education, philanthropy, and distribution partnerships.
- Market Dynamics: Breakdown of restructurings, joint ventures, terminations, and spinoffs impacting the CGT sector.
- Quarterly Analysis: Charts illustrating the frequency and types of deals throughout 2021, providing a clear view of market trends and activity changes per quarter.
Why This Report is Essential:
- Comprehensive Coverage: Tracks hundreds of cell and gene therapy deals, categorizing them into a usable format for easy reference.
- Market Insight: Offers in-depth analysis of key deals and strategic movements within the CGT industry.
- Investor Guidance: Provides valuable information for investors looking to understand the funding landscape and identify opportunities.
Additional Features:
- Vendor Profiles: Detailed profiles of leading companies involved in the CGT market.
- Visual Data Representation: Charts and graphs that visually represent deal activities and trends.
- Expert Analysis: Insights from Kalorama’s experienced analysts, offering expert perspectives on market developments.
Table: Total Quarterly Funding, By 2021 Quarter, By Type of Funding (in millions $) (%)
| Category | Q1 | Q2 | Q3 | Q4 | Total | % |
| M&A | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| VC/ Private | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| IPO/ FPO | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| SPAC | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Strat. Investment* | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Total | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
Table of Contents
Chapter 1: Executive Summary
Introduction
$70 Billion in Funding During 2021
- Table 1-1: Total Quarterly Funding, By 2021 Quarter, By Type of Funding [/M&A; Venture Capital/Private; IPO/FPO; and SPAC] (note: also Strat. Inv. $600M min) ($M) (%)
- Figure 1-1: Total Quarterly Funding, By 2021 Quarter, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M)
Quarterly Funding in 2021
- Figure 1-2: Q1 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
- Figure 1-3: Q2 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
- Figure 1-4: Q3 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
- Figure 1-5: Q4 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
903 CGT Announcements from January 2021 through January 2022
- Table 1-2: Quarterly Count of Deals, By 2021 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
Uptick in Collaborations, Acquisitions, and Manufacturing/Supply Chain Deals Highlight Activity in Cell and Gene Therapy
- Figure 1-6: Most Frequent Types of Deals, by 2021 Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (total number)
A Look at Less Frequent CGT Deal Types
- Figure 1-7: Lower Frequency Deal Types, by 2021 Quarter, by Category [Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number)
- Table 1-3: Monthly Count of Deals [January 2021-January 2022], By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number, n=903) (%)
- Figure 1-8: Total Deals per Month, January 2021-January 2022 (total number)
- Figure 1-9: Most Frequent Types of Deals, by Month [January 2021-January 2022], by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (total number)
- Figure 1-10: Lower Frequency Deal Types, by Month [January 2021-January 2022], by Category [Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number)
- Figure 1-11: Acquisition Amount, by Quarter [January 2021-January 2022] ($M)
- Figure 1-12: Venture Capital/Private Funding Round Amount, by Quarter [January 2021-January 2022] ($M)
- Figure 1-13: IPO/FPO Amount, by Quarter [January 2021-December 2021] ($M)
- Figure 1-14: SPAC Amount, 2021 ($M)
Chapter 2: Venture Capital & Private Funding
VC/Private Funding in Flux
- Table 2-1: Quarterly Venture Capital/Private Total Funding, By Quarter [January 2021-January 2022], By Region [North America, Europe, APAC, Rest of World] ($M)
- Figure 2-1: Quarterly Venture Capital/Private Total Funding, By Quarter [January 2021-January 2022], By Region [North America, Europe, APAC, Rest of World] ($M)
- Figure 2-2: Venture Capital/Private Funding Round Amount, By Quarter [January 2021-January 2022], ($M)
- Table 2-2: Venture Capital/Private, January 2022
- Table 2-3: Venture Capital/Private, Q4 2021
- Table 2-4: Venture Capital/Private, Q3 2021
- Table 2-5: Venture Capital/Private, Q2 2021
- Table 2-6: Venture Capital/Private, Q1 2021
Chapter 3: Strategic Investments
Strategic Investments in Cell and Gene Therapy
- Table 3-1: Strategic Investments, January 2021-January 2022
Chapter 4: IPOs, FPOs, & SPACs
North America Sees Majority of Proceeds from IPOs, FPOs, and SPACs
- Table 4-1: Quarterly IPO/FPO Funding, By Region [North America, APAC, and Europe) ($M)
- Figure 4-1: Quarterly IPO/FPO Funding, By Region [North America, APAC, and Europe) ($M)
- Figure 4-2: IPO/FPO Amount, By Quarter [January 2021-January 2022] ($M)
- Table 4-2: Disclosed Quarterly SPAC Funding Portion ($M)
- Figure 4-3: Disclosed Q1-Q4 and January 2022 SPAC Funding Portion ($M)
- Table 4-3: IPO/FPO Deals, Q4 2021
- Table 4-4: IPO/FPO Deals, Q3 2021
- Table 4-5: IPO/FPO Deals, Q2 2021
- Table 4-6: IPO/FPO Deals, Q1 2021
- Table 4-7: SPAC Piece, January 2021-January 2022 ($M)
- Figure 4-4: SPAC Amount, 2021 ($M)
Chapter 5: Mergers & Acquisitions (M&A)
2021 Sees Spike in M&A Activity During Q3
- Table 5-1: Quarterly Merger and Acquisition Totals, January 2021-January 2022 ($M)
- Figure 5-1: Acquisition Amount, By Quarter [January 2021-January 2022], ($M)
- Table 5-2: Mergers and Acquisitions, January 2022 ($M)
- Table 5-3: Mergers and Acquisitions, Q4 2021 ($M)
- Table 5-4: Mergers and Acquisitions, Q3 2021 ($M)
- Table 5-5: Mergers and Acquisitions, Q2 2021 ($M)
- Table 5-6: Mergers and Acquisitions, Q1 2021 ($M)
Chapter 6: Technology/Research/Strategic Collaborations
CGT Market Sees an Assortment of Collaborations
- Table 6-1: Technology/Research/Strategic Collaboration Deals, January 2021-January 2022
Chapter 7: Licensing
A Look at Licensing in the Cell and Gene Therapy Market
- Table 7-1: Licensing Deals, January 2021-January 2022
Chapter 8: Manufacturing and Supply Chain
Examining Manufacturing and Supply Chain Management Activity in CGT
- Table 8-1: Manufacturing and Supply Chain Deals, January 2021-January 2022
Chapter 9: Public Outreach, Consumer Education, & Philanthropy
CGT Market Has Dozens of Announcements Related to Public Outreach, Patient/Consumer Education, and Philanthropy
- Table 9-1: Outreach, Education, & Philanthropy Deals, January 2021-January 2022
Chapter 10: Distribution & Co-Marketing
A Look at CGT Distribution and Co-Marketing Deals
- Table 10-1: Distribution & Co-Marketing Deals, January 2021-January 2022
Chapter 11: Other – Conclusion, Restructuring, JV, Termination, Spinoffs
A Look at Other Types of Deals Impacting Cell and Gene Therapy
- Table 11-1: Restructuring, JV, Termination, Spinoffs Deal, January 2021-January 2022
Related products
Hematology and Coagulation Markets, 2023
April 5, 2023
Discover the lucrative $10 billion-dollar market for hematology and coagulation in vitro diagnostic (IVD) testing with Kalorama’s comprehensive report, Hematology and Coagulation Markets, 2023. This analysis delves into the dynamic growth factors driving this market, including new technologies, the aging population, and the increasing demand for decentralized testing.
Key Insights Provided:
- Market sizing…
$3,000.00 – $4,500.00
Cell Therapy and Gene Therapy Disease Markets, 2023-2029
April 30, 2024
Explore the future of medicine with our in-depth report on cell therapy, gene therapy, and RNA therapy markets. Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body’s immune system. Recent years have seen an increase in…
$5,000.00 – $7,875.00
The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition
March 7, 2024
Explore the cutting-edge world of molecular point-of-care (mPOC) diagnostic solutions with our latest report, offering a detailed analysis of the market and future growth potential from 2023-2028. mPOC technology revolutionizes diagnostic capabilities, providing enhanced sensitivity and specificity compared to traditional near-patient tests. These solutions are instrumental in critical care units, physician offices, outpatient clinics,…
$5,000.00 – $7,875.00
